无疾病活动证据的复发型多发性硬化中的沉默进展
该研究基于前瞻性队列,探讨临床复发和影像学疾病活动对长期残疾累积的贡献。结果显示复发仅与1年内短暂残疾增加相关,与确认的残疾进展无关;残疾进展者脑体积下降更快。作者提出「沉默进展」描述独立于复发的隐匿性残疾累积。
要点
- 复发与确认的残疾进展无关,仅引起短暂残疾增加。
- 残疾进展者脑萎缩速率更快。
- 传统复发缓解型患者中沉默进展常见。
核心结论
- 复发型多发性硬化患者长期恶化常见,且 largely 独立于复发活动,并与加速脑萎缩相关。
研究设计与样本
- 前瞻性队列研究,纳入复发型多发性硬化患者,随访至第10年。
主要发现
- 复发与1年间隔内短暂残疾增加相关(p = 0.012),但与确认的残疾进展无关(p = 0.551)。
- 残疾进展者相对脑体积下降速率高于稳定者(p < 0.05)。
关键数值与推荐
- 残疾进展定义为EDSS从基线增加1.5、1.0或0.5分(基线EDSS分别为0、1.0-5.0、5.5及以上),从基线至第5年(±1年)评估并持续至第10年(±1年)。
- 脑体积纵向分析采用线性混合模型,协变量包括性别、年龄、病程和HLA-DRB1*15:01。
临床怎么用
- 对满足传统复发缓解型标准且无疾病活动证据的患者,仍需监测残疾进展和脑萎缩。
- 临床评估应关注独立于复发的隐匿性残疾累积。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pretreatment era. Nonetheless, in our recently reported prospective cohort, more than half of patients with relapsing MS accumulated significant new disability by the 10th year of follow-up. Notably, "no evidence of disease activity" at 2 years did not predict long-term stability. Here, we determined to what extent clinical relapses and radiographic evidence of disease activity contribute to long-term disability accumulation. METHODS: Disability progression was defined as an increase in Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 (or greater) from baseline EDSS = 0, 1.0-5.0, and 5.5 or higher, respectively, assessed from baseline to year 5 (±1 year) and sustained to year 10 (±1 year). Longitudinal analysis of relative brain volume loss used a linear mixed model with sex, age, disease duration, and HLA-DRB1*15:01 as covariates. RESULTS: Relapses were associated with a transient increase in disability over 1-year intervals (p = 0.012) but not with confirmed disability progression (p = 0.551). Relative brain volume declined at a greater rate among individuals with disability progression compared to those who remained stable (p < 0.05). INTERPRETATION: Long-term worsening is common in relapsing MS patients, is largely independent of relapse activity, and is associated with accelerated brain atrophy. We propose the term silent progression to describe the insidious disability that accrues in many patients who satisfy traditional criteria for relapsing-remitting MS. Ann Neurol 2019;85:653-666.
引用
- Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019. PMID: 30851128. doi:10.1002/ana.25463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。